Latest Data of InnoCare's Zurletrectinib Orally Presented at SIOP 2025
Seeking Alpha / 1 hour from now 1 Views
Zurletrectinib demonstrated well-tolerated safety and promising antitumor activity in pediatric/adolescent patients with NTRK/ROS1-altered solid tumors.
Comments